Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by ($0.06), Zacks reports. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.96% and a net margin of 4.88%.The company had revenue of $5.34 billion for the quarter, compared to the consensus estimate of $5.41 billion.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $21.04 on Thursday. The business has a 50-day simple moving average of $22.70 and a 200 day simple moving average of $23.47. The firm has a market capitalization of $11.75 billion, a price-to-earnings ratio of 11.08, a PEG ratio of 2.46 and a beta of 0.81. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.26 and a quick ratio of 0.92. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.02 and a one year high of $30.46.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The company also recently announced an annual dividend, which will be paid on Monday, June 8th. Stockholders of record on Friday, May 22nd will be paid a $0.8716 dividend. The ex-dividend date is Friday, May 22nd. This represents a dividend yield of 385.0%. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio (DPR) is 29.84%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, April 24th. Wall Street Zen cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Weiss Ratings cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, March 13th. The Goldman Sachs Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. Finally, Erste Group Bank cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Six analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $28.00.

Read Our Latest Stock Analysis on FMS

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently added to or reduced their stakes in FMS. XTX Topco Ltd lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 743.3% during the fourth quarter. XTX Topco Ltd now owns 94,093 shares of the company’s stock worth $2,241,000 after acquiring an additional 82,935 shares during the period. OLD Mission Capital LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter valued at about $276,000. Engineers Gate Manager LP grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 217.6% during the 4th quarter. Engineers Gate Manager LP now owns 33,854 shares of the company’s stock valued at $806,000 after acquiring an additional 23,194 shares during the period. Balyasny Asset Management L.P. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at approximately $1,799,000. Finally, AQR Capital Management LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 15.0% during the 4th quarter. AQR Capital Management LLC now owns 37,315 shares of the company’s stock worth $889,000 after purchasing an additional 4,876 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get Free Report)

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.

Further Reading

Earnings History for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.